Connect with us

PR Newswire

Estudo clínico iniciado com novo spray nasal codinome APR-AOS2020 em pacientes com COVID-19 moderada

Published

on

BALERNA, Suíça, 13 de maio de 2021 /PRNewswire/ — A APR Applied Pharma Research S.A. (APR), líder no desenvolvimento de tecnologias e sistemas de distribuição de medicamentos farmacêuticos e produtos inovadores derivados dos mesmos, anunciou hoje o início de um estudo clínico principal para avaliar a eficácia de seu produto codinome temporário APR-AOS2020, um dispositivo médico de classe III, no tratamento de pacientes de COVID-19 com sintomas moderados. O estudo está sendo conduzido pela unidade de higiene do Hospital IRCCS Policlinico San Martino em Genoa, Itália, e coordenado pelo Prof. Giancarlo Icardi como investigador principal. O estudo foi planejado para cadastrar um total de 57 pacientes com COVID-19 que apresentem sintomas leves da doença e está avaliando a eficácia e a segurança do produto em spray na redução da carga viral nas vias respiratórias superiores em indivíduos recentemente infectados. Quando disponíveis, os resultados podem representar o ponto de partida para o uso do produto na prevenção de sintomas mais graves, na redução do risco de infecção e propagação do vírus.

O HCLO é uma substância natural produzida pelo próprio sistema imunológico inato do organismo (neutrófilos) para combater infecções causadas por vários microrganismos. O APR-AOS2020 foi desenvolvido utilizando a plataforma de entrega de nanotecnologia Tehclo™ da APR, que “aprisiona” HCLO em uma solução aquosa, permitindo que seja inalado e purificando e estabilizando a substância natural. O mecanismo de ação do spray Sentinox baseia-se na ação de limpeza da solução que, sustentada pela potente atividade antimicrobiana do HCLO, é capaz de remover e eliminar em menos de um minuto vírus e bactérias, incluindo o SARS-CoV-2 e suas várias mutações e variantes, sem irritar a mucosa nasal e da garganta.  Os resultados dos testes in vitro com o Sentinox conduzidos pelo Instituto de Pesquisa Antiviral da Universidade do Estado de Utah respaldam esse mecanismo de ação e capacidade de eliminar vírus e bactérias rapidamente.[1]

Estudos clínicos em seres humanos, bem como testes de segurança in vitro e in vivo, demonstraram que o APR-AOS2020 tem um perfil de segurança muito bom em vários tecidos humanos com um índice de citotoxicidade até 20 vezes menor do que outras soluções antimicrobianas comercializadas.

Com base nesses dados animadores, desenvolvemos um estudo clínico principal, monocêntrico, randomizado e controlado para avaliar se a solução em spray, usada para irrigar, hidratar e limpar a mucosa nasal três ou cinco vezes por dia em intervalos regulares, é segura e eficaz em pacientes positivos para SARS-CoV-2 com sintomas leves, além das terapias padrão, para reduzir a carga viral nasal – disse o ProfessorGiancarlo Icardi, diretor da unidade de higiene do Hospital IRCCS Policlinico San Martino em Gênova, investigador principalA redução da carga viral no nariz, graças ao mecanismo de limpeza mecânica combinado com a eficácia antimicrobiana do HCLO, poderia prevenir a ocorrência de sintomas mais graves e melhorar o curso da doença em sua fase inicial, reduzindo também o risco de propagação da infecção a outros indivíduos. Se a carga viral do SARS-CoV-2 nas vias respiratórias superiores for menor, é possível que a probabilidade do vírus entrar nas vias respiratórias inferiores danificando os pulmões seja reduzida. O spray nasal, quando utilizado na fase inicial de infecção ou após exposição ao risco de infecção, poderia reduzir a probabilidade de infecção, o agravamento dos sintomas e a propagação da infecção para outros indivíduos“.

Acreditamos que este dispositivo inovador, desenvolvido para ser acessível e fácil de usar, poderia representar uma opção de proteção adicional de curto prazo que poderia ser particularmente útil em ambientes de alto risco, como transporte público, lojas, escolas e outros espaços cheios e fechados”, disse Paolo Galfetti, CEO da APR.  “O início deste estudo clínico controlado e randomizado nos aproxima do objetivo de disponibilizar este produto antes do final do ano especificamente para uso contra a COVID-19.

Sobre a APR Applied Pharma Research s.a. (“APR”) 

A APR é uma empresa farmacêutica independente com sede na Suíça com subsidiárias na Itália e Alemanha focada, há mais de 25 anos, no desenvolvimento e comercialização de produtos destinados a melhorar a qualidade de vida de pacientes e famílias que lidam com doenças graves de alta necessidade médica. O portfólio da APR inclui produtos para o tratamento de doenças raras ou de nicho, que são comercializados em cerca de 50 países em todo o mundo, diretamente ou por meio de acordos de licenciamento e distribuição com parceiros selecionados. O pipeline inclui produtos em diferentes estágios de desenvolvimento concentrados em três áreas terapêuticas selecionadas: doenças recessivas metabólicas hereditárias, cuidados com o câncer e doenças raras da pele. Para mais informações, acesse: https://www.apr.ch/

Sobre a APR-AOS2020 

APR-AOS2020 é uma solução oxidante de ácido (AOS) que contém ácido hipocloroso a 0,005%, certificada e autorizada na Europa em 5de março de 2021 como dispositivo médico de classe III (Certificado nº EPT 0477.MDD.21/4200,1 com nome provisório Sentinox). O dispositivo é destinado à irrigação, limpeza e umedecimento das cavidades nasais e é indicado para (i) reduzir o risco de infecções causadas por bactérias e vírus, incluindo SARS-CoV-2, por meio da redução da carga microbiana nasal, (ii) cuidados nasais sintomáticos e (iii) cuidados nasais em caso de lesões/alterações menores da mucosa nasal.

Logotipo – https://mma.prnewswire.com/media/1194581/APR_Applied_Pharma_Research_Logo.jpg

Contatos: 

APR Applied Pharma Research s.a.
Paolo Galfetti, CEO
[email protected]
+41 91 6957020

[1] https://link.springer.com/article/10.1007/s00405-021-06644-5

FONTE APR Applied Pharma Research s.a.

Related Links

www.apr.ch

SOURCE APR Applied Pharma Research s.a.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/estudo-clinico-iniciado-com-novo-spray-nasal-codinome-apr-aos2020-em-pacientes-com-covid-19-moderada-842135695.html

PR Newswire

Oleochemicals Market|$ 9.01 billion growth expected during 2021-2025 | 17000+ Technavio Reports

Published

on

Technavio’s in-depth market research reports include value chain analysis and validation techniques to help industry leaders improve their business.
Download FREE Sample Report

The report on the oleochemicals market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by factors such as the growth of packaged food and beverage industry, the growing demand for soaps and detergents, and government initiatives regarding the use of oleochemicals.

The oleochemicals market analysis includes the product, application, and geography landscape segments. This study identifies the government initiatives regarding the use of oleochemicals as one of the prime reasons driving the oleochemicals market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The oleochemicals market covers the following areas:

Oleochemicals Market Sizing
Oleochemicals Market Forecast
Oleochemicals Market Analysis

Companies Mentioned

  • BASF SE
  • Cabot Corp.
  • Cargill Inc.
  • Croda International Plc
  • Emery Oleochemicals Group
  • IOI Corporation Berhad
  • Kao Corp.
  • KLK Oleo
  • The Procter and Gamble Co.
  • Wilmar International Ltd.

Related Reports on Materials Include:

Global Ink Resins Market– The ink resins market size is segmented by process (lithography printing, flexography printing, gravure printing, and others) and geography (APAC, Europe, North America, MEA, and South America).
Download FREE Sample Report

Global Emulsion Polymers Market– The emulsion polymers market is segmented by application (paints and coatings, paper and paperboard coatings, adhesives, and others) and geography (APAC, North America, Europe, South America, and MEA).
Download FREE Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020- 2025

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Fatty acids – Market size and forecast 2020-2025
  • Fatty alcohol – Market size and forecast 2020-2025
  • Glycerol – Market size and forecast 2020-2025
  • Fatty amines – Market size and forecast 2020-2025
  • Others – Market size and forecast 2020-2025
  • Market opportunity by Product

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Soaps and detergents – Market size and forecast 2020-2025
  • Polymers – Market size and forecast 2020-2025
  • Personal care and pharmaceuticals – Market size and forecast 2020-2025
  • Lubricants and greases – Market size and forecast 2020-2025
  • Others – Market size and forecast 2020-2025
  • Market opportunity by Application

Customer landscape

  • Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • APAC – Market size and forecast 2020-2025
  • North America – Market size and forecast 2020-2025
  • Europe – Market size and forecast 2020-2025
  • MEA – Market size and forecast 2020-2025
  • South America – Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • BASF SE
  • Cabot Corp.
  • Cargill Inc.
  • Croda International Plc
  • Emery Oleochemicals Group
  • IOI Corporation Berhad
  • Kao Corp.
  • KLK Oleo
  • The Procter and Gamble Co.
  • Wilmar International Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Newsroom:  https://www.technavio.com/news/oleochemicalsmarket
Report Page: https://www.technavio.com/report/oleochemicals-market-industry-analysis

SOURCE Technavio

Related Links

https://www.technavio.com/report/oleochemicals-market-industry-analysis?utm_source=prnewswire&utm_medium=pressrelease&utm_campaign=T41-v1_wk26_005_&utm_content=IRTNTR70600

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/oleochemicals-market-9-01-billion-growth-expected-during-2021-2025–17000-technavio-reports-301315819.html

Continue Reading

PR Newswire

Top Italian Bank, Credem Goes Live with Temenos Infinity in the Cloud to Deliver Frictionless Digital Experiences

Published

on

  • Temenos Infinity powers rapid time-to-market for new digital banking experiences, starting from a brand new mobile app for Retail and SME customers
  • New app enables Credem to greatly improve its customer experience and achieve a first-class omnichannel experience

GENEVA, Switzerland, June 22, 2021 /PRNewswire/ — Temenos (SIX: TEMN), the banking software company, today announced that Credito Emiliano S.p.A. (Credem), one of the top 10 banks in Italy, has gone live with a new mobile app, based on cloud-native Temenos Infinity, to accelerate its digital banking strategy. Temenos Infinity, running on the public cloud, will make it quicker and easier for Credem to develop frictionless, personalized, and secure digital banking services that will help it attract new customers and drive long-term customer loyalty.

Credem has already launched a fully renewed new mobile app developed in just nine months using Temenos Infinity. The new app offers a basic set of features for personal customers and, thanks to the speed granted by Temenos Infinity, will be enriched with new features in a continuous improvement approach. A small business version will follow in a few months. It includes features that make it easy and convenient to move money, view transactions, check and manage cards, including the re-charge of pre-paid cards and phone tops ups, and initiate instant chat with customer support agents or view the locations of nearest ATMs.

In a highly competitive Italy market, Credem’s new app with its advanced customer interface and user experience will help to enhance the bank’s digital reputation and give it an edge to compete with larger banks and ultimately grow market share.

Temenos Infinity allows Credem to create intuitive and highly engaging digital experiences using a low-code development platform. This simplifies the process, saving time and cost. It also means Credem can reimagine how to engage with its customers in a whole new way through digital and physical channels, creating a consistent and seamless experience.

Temenos Infinity provides a portal for bank staff to manage and assist account holders in their banking journeys. It collects everything the banker needs to know about their account holder in a convenient web-based interface, with data matching that the account holder sees from their own mobile or online interface. Banks using Temenos Infinity saw customer engagement increase by up to 300 percent on their apps in 2020, with the fastest-growing segment being among baby boomers and Gen Xers.

Fabio Caliceti, Head of Digital Channels, Credito Emiliano, commented: “With Temenos, we have been able to quickly develop a mobile banking experience to compete with the very best in Italy. Temenos Infinity gives us the platform we need to efficiently build and manage exceptional digital banking experiences that keep pace with changing customer needs. It is strategic to our digital growth plans and enables us to future-proof our customer relationships.”

David Macdonald, President of Europe, Temenos, said: “Digital innovation in banking is thriving in Italy, and it’s an important market for Temenos where we have a strong and growing presence. So we are delighted Credem has selected our digital banking platform to accelerate its digital strategy. Credem has shown how Temenos Infinity can deliver outstanding digital mobile experiences in a very short timeframe. Customer expectations are constantly evolving, but with the continuous innovation and deployment capabilities of the platform, Credem will always be one step ahead of the competition.”

Credem is running Temenos Infinity on the public cloud with Amazon Web Services to achieve hyperscaler efficiency, security, and resilience for its digital banking services. Temenos Infinity is cloud-native and cloud-agnostic and also available as a SaaS offering on The Temenos Banking Cloud.

Temenos Infinity drives customer acquisition and digital banking engagement with its advanced analytics, enabling financial institutions to increase digital revenues 5x and cut customer onboarding time by 75%. Financial institutions that use Temenos Infinity report a 20% higher Net Promoter Score.

Temenos Infinity is used by over 650 banks worldwide and recognized as a Market Leader in Omdia’s Digital Banking Platform Report and a Leader in Digital Banking Engagement by Forrester.

Following the successful launch of its mobile app, Credem plans to further leverage Temenos Infinity to enhance the customer experience for internet banking later in 2021.

About Credito Emiliano S.p.A.

Credito Emiliano S.p.A. (Credem) is an Italian bank based in Reggio Emilia, Emilia-Romagna. The bank is listed in the Italian Stock Exchange. Credem has more than 6000 employees and presence in different markets:  Banca Credem (retail banking), Credem Banca d’Impresa (corporate banking), Credem Private Banking.

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com.

SOURCE Temenos

Related Links

http://www.temenos.com

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/top-italian-bank-credem-goes-live-with-temenos-infinity-in-the-cloud-to-deliver-frictionless-digital-experiences-301316691.html

Continue Reading

PR Newswire

Photocure: Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Published

on

OSLO, Norway, June 22, 2021 /PRNewswire/ — Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals (Asieris) has administered the first European patient in its phase III clinical trial for APL-1702 (Cevira®).

Asieris announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial called APRICITY that started last November. The photodynamic drug-device combination product APL-1702, Cevira®, licensed to Asieris by Photocure, is being developed for a novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL).

“The multinational phase III clinical trial for Cevira is an important milestone towards a non-surgical treatment of high-grade cervical dysplasia. This step shows once more that our partner Asieris is making great progress and is on track with their clinical program and development of this innovative photodynamic drug-device combination,” says Daniel Schneider, Chief Executive Officer of Photocure.

In China, the clinical trial application for APL-1702, Cevira multinational Phase III trial was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in July 2020. Photocure reported Asieris’ dosing of the first patient in China on November 11, 2020 (https://photocure.com/news/asieris-announces-first-patient-administration-in-the-global-phase-iii-clinical-trial-for-apl-1702-cevira/).

HSIL is a pre-cancerous condition caused by a persistent HPV infection. Each year there are approximately 10 million cases of high-grade disease and over 500,000 new cases of cervical cancer worldwide. In China, approximately 2% of women develop HSIL each year.

Please read Asieris’ full press release here: https://asieris.com/asieris-announces-first-patient-treated-in-europe-in-apricity-the-multinational-phase-iii-clinical-trial-of-apl-1702-cevira/ 

Note to editors:

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
 

About Cevira

Cevira® is a photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade cervical dysplasia. Cevira is easily placed on the cervix by the gynecologist and removed by the patient, with no disruption of normal daily activities. Only one or two treatments are needed.

About Cervical dysplasia

High grade cervical squamous intraepithelial lesions (HSIL) is a precancerous condition caused by a persistent HPV infection, a highly prevalent sexually transmitted disease resulting in approximately 10 million cases with high grade disease and > 500 000 new cases of cervical cancer each year. In China, approximately 2% of women have HSIL each year. Currently, surgical excision is the most common treatment option offered to women with cervical high-grade dysplasia. In women of childbearing age in particular there is a high medical need for a non-surgical option which preserves the cervical anatomy and function. No such medical alternative is approved to date.

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

CONTACT:

Dan Schneider, President and CEO, Photocure ASA
Email: [email protected]

Erik Dahl, CFO, Photocure ASA
Tel: +4745055000
Email: [email protected]

David Moskowitz, Head of Investor Relations, Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]

Media and IR enquiries:

Geir Bjørlo, Corporate Communications (Norway), Photocure ASA
Tel: +47 91540000
Email: [email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/photocure–asieris-announces-first-patient-administration-in-europe-within-the-phase-iii-clinical-tr,c3371671

The following files are available for download:

SOURCE Photocure

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/photocure-asieris-announces-first-patient-administration-in-europe-within-the-phase-iii-clinical-trial-for-apl-1702-cevira-301316974.html

Continue Reading

PR Newswire

European Wellness Advances Clinical Trials on Precursor Stem Cells for Fertility and Immunology into China

Published

on

In a virtual signing session via Zoom Meeting, the Sino-European alliance agreed to enter into a strategic venture involving European Wellness’ proprietary precursor (progenitor) stem cells and biological peptides at Li Hua Biotechnology’s CGTP research facility and Hunan’s Xiangtan Central Hospital, the first large-scale national first-class general hospital in Xiangtan City. This multi-phase alliance ultimately aims to create best-in-class modern cell therapeutics that are made accessible to the local community in China.

Li Hua Biotechnology was represented by Director Prof. Dr. Tham Xiao Jun, while European Wellness was represented by Group Chairman Prof. Dr. Mike Chan during the June 11th MOU signing.

The partnership manifests European Wellness’ efforts to propel the development of its proprietary patent-pending precursor stem cell therapeutics, which presently is in the early stage of multi-centric clinical development across USA, Greece and Japan led by European Wellness’ international scientific committee which constitutes world-class researchers with profound scientific pedigree including Massachusetts Institute of Technology (MIT), University of Southern California, University of California-Irvine, Oxford University, Cambridge University and Germany’s renowned Heidelberg University, where safety and toxicity studies, and further research studies are undergoing.

The later phase of the strategic venture focalizes on providing education to researchers and local medical practitioners in China, particularly in the specialised subject of bio-regenerative science as well as clinical protocols and best practices in stem cell transplantation.

National Bureau of Statistics of China revealed that China’s birthrate has drastically decline in recent years with only 12 million babies born last year compared to the 18 million born in 2016 (the lowest number of births recorded by China since the 1960s).

“Although in-vitro fertilization (IVF) is a popular option among Chinese couples, it may not always work. The likelihood of IVF success deteriorates after the age of 35,” said Prof. Dr. Mike Chan.

“This is where organ-specific precursor stem cell therapy may be of service as it targets the regeneration of specific organs linked with the pathophysiology of infertility. This is achieved through non-invasive transplantation of a variety of precursor stem cells originating from the pituitary, adrenal gland, liver and the gonads.”

His sentiments were shared by Prof. Tham, China’s renowned gynaecologist with specialisation in IVF and a prominent stem cell scientist since 2005, who believed that this alliance signifies the convergence of great intellects from the East and West in this emerging scientific sphere.

“With China’s three-child policy announced in May 2021 to address the ageing population problem, European Wellness as a pioneer and leader in stem cell therapeutics is indeed a worthy partner to collaborate with and address the escalating demand for non-invasive fertility therapy in China.”

European Wellness Biomedical Group

European Wellness Biomedical Group is an award-winning European group founded in 1991 in Switzerland through the culmination of early cell therapeutic research efforts spanning across Switzerland, Germany, Russia and Austria since the mid ’80s. Today, the Group is most renowned for its pioneering developments in precursor stem cell therapeutics, biological peptides, biological regenerative medicine and immunomodulation. The Group’s multinational business divisions include research and development, bio-manufacturing, medical academy and education, anti-ageing centres and product distribution to practitioners and consumers across 80 countries. The Group also owns a growing network of 26 internationally accredited Wellness Centres globally. Today, the Group is headquartered in Germany and Kota Kinabalu, Malaysia (Asia Pacific) with research facilities in Germany, Switzerland, Czech Republic and United Kingdom.

https://european-wellness.eu

SOURCE European Wellness Biomedical Group

Related Links

https://european-wellness.eu

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-wellness-advances-clinical-trials-on-precursor-stem-cells-for-fertility-and-immunology-into-china-301316968.html

Continue Reading
Esports5 days ago

Select Smart Genshin Impact: How to Make the Personality Quiz Work

Esports2 days ago

Dungeons & Dragons: Dark Alliance Voice Actors: Who Voices Utaar?

Blockchain5 days ago

Bitmain Released New Mining Machines For DOGE And LTC

Blockchain2 days ago

Is Margex A Scam?

Esports4 days ago

Genshin Impact Grand Line Conch Locations

Energy3 days ago

Inna Braverman, Founder and CEO of Eco Wave Power Will be Speaking at the 2021 Qatar Economic Forum, Powered by Bloomberg

Esports2 days ago

Valorant Patch 3.00 Agent Tier List

Blockchain2 days ago

Yearn Finance (YFI) and Synthetix (SNX) Technical Analysis: What to Expect?

HRTech1 day ago

TCS bats for satellite offices, more women in the workforce

Esports5 days ago

Chivalry 2 Crossplay Not Working: Is There a Fix?

Esports5 days ago

5 Things to Do Before Shadowlands 9.1

AI2 days ago

New Modular SaaS Platform for Financial Services Sector Launched by Ezbob, a Customer Acquisition Tech Provider

Esports2 days ago

Is Dungeons and Dragons: Dark Alliance Crossplay?

Aviation3 days ago

SAS Was The First Airline To Operate A Polar Route

Blockchain3 days ago

Cardano, Chainlink, Filecoin Price Analysis: 21 June

Esports2 days ago

Ruined Pantheon Prestige Edition Splash Art, Price, Release, How to Get

Blockchain4 days ago

Amplifying Her Voice June 22, 10:45AM to June 24, 4:00PM EST BERMUDA

Aviation4 days ago

The Antonov An-124 Vs An-225: What Are The Differences?

Aviation5 days ago

KLM’s Fleet In 2021

Crowdfunding5 days ago

Top 10 Fintech News Stories for the Week Ending June 19, 2021

Trending